

**ACI Formulations Limited**


**1st Quarter Report 2022-2023**


ACI Formulations Limited


Statement of financial position  
Unaudited


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2022	As at 30 June 2022
<b>Assets</b>			
Property, plant and equipment	5	2,376,489	2,362,781
Right-of-use assets		11,126	12,780
Investments	6	60,752	42,752
<b>Non-current assets</b>		<b>2,448,367</b>	<b>2,418,313</b>
Inventories	8	2,269,603	1,360,588
Trade receivables	9	1,314,260	1,112,101
Other receivables		59,783	75,902
Inter-company receivables	10	518,456	826,785
Advances, deposits and prepayments	11	62,537	44,813
Current tax assets		447,651	411,121
Cash and cash equivalents		218,857	223,436
<b>Current assets</b>		<b>4,891,147</b>	<b>4,054,746</b>
<b>Total assets</b>		<b>7,339,514</b>	<b>6,473,059</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,619,739	1,619,739
Retained earnings		1,098,842	1,024,819
<b>Total equity</b>		<b>3,191,081</b>	<b>3,117,058</b>
<b>Liabilities</b>			
Employee benefits	12	63,873	60,606
Lease liabilities		7,524	8,309
Deferred tax liabilities		28,366	34,191
<b>Non-current liabilities</b>		<b>99,763</b>	<b>103,106</b>
Bank overdrafts		113,886	113,568
Loans and borrowings		3,181,839	2,572,417
Lease liabilities- current portion		4,112	4,966
Trade payables		264,391	96,881
Other payables	13	479,182	459,797
Unclaimed dividend account	14	5,260	5,266
<b>Current liabilities</b>		<b>4,048,670</b>	<b>3,252,895</b>
<b>Total liabilities</b>		<b>4,148,433</b>	<b>3,356,001</b>
<b>Total equity and liabilities</b>		<b>7,339,514</b>	<b>6,473,059</b>
<b>Net asset value (NAV) per share</b>		<b>67.54</b>	<b>65.97</b>

  
 Managing Director

  
 Director

  
 Chief Financial Officer


  
 Company Secretary


ACI Formulations Limited


Statement of profit or loss and other comprehensive income  
Unaudited


Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2022 to September 2022	July 2021 to September 2021
Revenue	15	1,292,891	1,019,826
Cost of sales	16	(953,786)	(734,101)
<b>Gross profit</b>		<b>339,105</b>	<b>285,725</b>
Other income		4,763	768
Administrative, selling and distribution expenses	17	(202,713)	(179,967)
<b>Operating profit</b>		<b>141,156</b>	<b>106,526</b>
<b>Finance costs, net</b>		<b>(39,176)</b>	<b>(30,395)</b>
<b>Profit before contribution to WPPF</b>		<b>101,980</b>	<b>76,131</b>
Contribution to WPPF		(5,099)	(3,807)
<b>Profit before tax</b>		<b>96,881</b>	<b>72,324</b>
Tax expenses		(22,858)	(19,575)
<b>Profit after tax</b>		<b>74,023</b>	<b>52,749</b>
Other comprehensive income		-	-
<b>Total comprehensive income</b>		<b>74,023</b>	<b>52,749</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)		1.57	1.12

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

**ACI Formulations Limited**  
**Statement of changes in equity**  
**Unaudited**

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2022			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2022</b>	472,500	1,619,739	1,024,819	3,117,058
<b>Total comprehensive income</b>				
Profit for the period	-	-	74,023	74,023
<b>Total comprehensive income</b>	-	-	74,023	74,023
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2022</b>	472,500	1,619,739	1,098,842	3,191,081

<i>In Taka</i>	For the 1st quarter ended 30 September 2021			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2021</b>	450,000	1,619,739	939,636	3,009,375
<b>Total comprehensive income</b>				
Profit for the period	-	-	52,749	52,749
<b>Total comprehensive income</b>	-	-	52,749	52,749
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2021</b>	450,000	1,619,739	992,385	3,062,124

**ACI Formulations Limited**

**Statement of cash flows  
Unaudited**

**Figures in "000"**

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2022 to September 2022	July 2021 to September 2021
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,109,488	1,008,785
Cash paid to suppliers and employees		(1,918,523)	(1,061,885)
Cash (used in)/generated from operating activities		<b>(809,035)</b>	<b>(53,100)</b>
Interest paid		(5,976)	(9,510)
Income tax paid		(65,212)	(38,888)
		<b>(71,188)</b>	<b>(48,398)</b>
<b>Net cash (used in)/generated from operating activities*</b>	18	<b>(880,223)</b>	<b>(101,498)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(24,905)	(1,299)
Investment		(18,000)	
<b>Net cash (used in)/generated from investing activities</b>		<b>(42,905)</b>	<b>(1,299)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		310,455	(337,614)
Proceeds from loans and borrowings		609,422	315,215
Payment for lease liability		(1,639)	1,735
Dividends paid		(6)	(8,086)
<b>Net cash (used in)/generated from financing activities</b>		<b>918,232</b>	<b>(28,750)</b>
Net increase in cash and cash equivalents		<b>(4,897)</b>	<b>(131,547)</b>
Cash and cash equivalents as at 1 July		109,867	83,700
<b>Cash and cash equivalents as at 30 September</b>		<b>104,970</b>	<b>(47,847)</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		218,857	141,269
Bank overdraft		(113,886)	(189,116)
		<b>104,970</b>	<b>(47,847)</b>
<b>Net operating cash flow per share (NOCFPS)</b>		<b>(18.63)</b>	<b>(2.15)</b>

\* See Note 18 for reconciliation of net operating cash flow.


**ACI Formulations Limited**  
**Consolidated Statement of Financial Position**  
**Unaudited**


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2022	As at 30 June 2022
<b>Assets</b>			
Property, plant and equipment	5(a)	2,377,035	2,363,419
Right-of-use assets		11,126	12,780
Investments	6(a)	38,804	38,804
Intangible assets	7	5,148	5,148
<b>Non-current assets</b>		<b>2,432,113</b>	<b>2,420,151</b>
Inventories	8(a)	2,269,603	1,360,588
Trade receivables	9(a)	1,314,908	1,112,572
Other receivables		59,783	75,902
Inter-company receivable	10(a)	510,053	819,150
Advances, deposits and prepayments	11(a)	63,188	45,464
Current tax assets		447,429	410,952
Cash and cash equivalents		240,018	224,597
<b>Current assets</b>		<b>4,904,982</b>	<b>4,049,225</b>
<b>Total assets</b>		<b>7,337,095</b>	<b>6,469,376</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,619,739	1,619,739
Retained earnings		1,093,821	1,020,448
<b>Equity attributable to the owner of the Company</b>		<b>3,186,060</b>	<b>3,112,687</b>
Non controlling interest		1,793	(114)
<b>Total equity</b>		<b>3,187,853</b>	<b>3,112,573</b>
<b>Liabilities</b>			
Employee benefits	12	63,873	60,606
Lease liabilities		7,524	8,309
Deferred tax liabilities		28,324	34,149
<b>Non-current liabilities</b>		<b>99,721</b>	<b>103,064</b>
Bank overdrafts		113,886	113,568
Loans and borrowings		3,181,839	2,572,417
Lease liabilities- current portion		4,112	4,966
Trade payables		264,709	97,198
Other payables	13(a)	479,715	460,324
Unclaimed dividend account	14	5,260	5,266
<b>Current liabilities</b>		<b>4,049,521</b>	<b>3,253,739</b>
<b>Total liabilities</b>		<b>4,149,242</b>	<b>3,356,803</b>
<b>Total equity and liabilities</b>		<b>7,337,095</b>	<b>6,469,376</b>
<b>Net asset value (NAV) per share</b>	19	<b>67.43</b>	<b>65.88</b>

  
 Managing Director

  
 Director

  
 Chief Financial Officer

  
 Company Secretary



ACI Formulations Limited

Consolidated statement of profit or loss and other comprehensive income  
Unaudited


Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2022 to September 2022	July 2021 to September 2021
Revenue	15(a)	1,293,428	1,020,115
Cost of sales	16(a)	(953,786)	(734,101)
<b>Gross profit</b>		<b>339,642</b>	<b>286,014</b>
Other income		4,763	793
Administrative, selling and distribution expenses	17(a)	(203,781)	(180,062)
<b>Operating profit</b>		<b>140,624</b>	<b>106,745</b>
Finance costs, net		(39,333)	(30,559)
<b>Profit before contribution to WPPF</b>		<b>101,291</b>	<b>76,186</b>
Contribution to WPPF		(5,099)	(3,807)
<b>Profit before tax</b>		<b>96,192</b>	<b>72,379</b>
Income tax expenses		(22,912)	(19,604)
<b>Profit after tax</b>		<b>73,280</b>	<b>52,775</b>
<b>Other comprehensive income</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income</b>		<b>73,280</b>	<b>52,775</b>
<b>Total comprehensive income attributable to:</b>			
Owners of the Company		73,373	52,774
Non controlling interest		(93)	1
		<b>73,280</b>	<b>52,775</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)	19	1.55	1.12

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity  
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2022					
	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2022</b>	472,500	1,619,739	1,020,448	3,112,687	(114)	3,112,573
<b>Total comprehensive income</b>						
Profit for the period	-	-	73,373	73,373	(93)	73,280
<b>Total comprehensive income</b>	-	-	73,373	73,373	(93)	73,280
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
Capital contribution by non-controlling interest	-	-	-	-	2,000	2,000
<b>Total transactions with owners of the company</b>	-	-	-	-	2,000	2,000
<b>Balance at 30 September 2022</b>	472,500	1,619,739	1,093,821	3,186,060	1,793	3,187,853

<i>In Taka</i>	For the 1st quarter ended 30 September 2021					
	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2021</b>	450,000	1,619,739	935,071	3,004,810	(118)	3,004,692
<b>Total comprehensive income</b>						
Profit for the period	-	-	52,774	52,774	1	52,775
<b>Total comprehensive income</b>	-	-	52,774	52,774	1	52,775
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-	-	-
<b>Balance at 30 September 2021</b>	450,000	1,619,739	987,845	3,057,584	(117)	3,057,467



**ACI Formulations Limited**  
**Consolidated statement of cash flows**  
**Unaudited**

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from July 2022 to September 2022	July 2021 to September 2021
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,109,849	1,009,066
Cash paid to suppliers and employees		(1,919,494)	(1,061,822)
Cash (used in)/generated from operating activities		<b>(809,645)</b>	<b>(52,756)</b>
Interest paid		(6,134)	(9,674)
Income tax paid		(65,212)	(38,888)
		<b>(71,346)</b>	<b>(48,562)</b>
<b>Net cash (used in)/generated from operating activities*</b>	<b>18 (a)</b>	<b>(880,991)</b>	<b>(101,318)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(24,905)	(1,299)
Investment		2,000	
<b>Net cash (used in)/generated from investing activities</b>		<b>(22,905)</b>	<b>(1,299)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		311,222	(337,339)
Proceeds from loans and borrowings		609,422	315,216
Payment for lease liability		(1,639)	1,735
Dividends paid		(5)	(8,086)
<b>Net cash (used in)/generated from financing activities</b>		<b>919,000</b>	<b>(28,474)</b>
Net increase in cash and cash equivalents		15,104	<b>(131,091)</b>
Cash and cash equivalents as at 1 July		<b>111,028</b>	<b>84,495</b>
<b>Cash and cash equivalents as at 30 September</b>		<b>126,132</b>	<b>(46,596)</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		240,018	142,520
Bank overdraft		(113,886)	(189,116)
		<b>126,132</b>	<b>(46,596)</b>
<b>Net operating cash flow per share (NOCFPS)</b>	<b>19</b>	<b>(18.65)</b>	<b>(2.14)</b>

\* See Note 18(a) for reconciliation of consolidated net operating cash flow.

## ACI Formulations Limited

### Notes to the financial statements as at and for the 1st quarter ended on 30 September 2022 Unaudited

**1 Company profile:**

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

**2 Subsidiaries of ACI Formulations Limited:**

**Neem Laboratories (Pvt.) Ltd.**

Neem Laboratories (Pvt.) Ltd generate its revenue through royalty fees based on the agreement with ACI Limited effective from 1 July 2019 for a tenure of 5 years; the later currently being engaged in the manufacturing of products under the Neem brand name. Since the Subsidiary showed profitability during the year, its ability to operate as a going concern is not at risk. ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

**ACI AgroChem (Pvt.) Ltd.**

ACI AgroChem was incorporated on 22nd June 2022 as a limited Company. The principal activities of the Company is to manufacture and marketing of various kinds of agricultural input like chemical including other allied and general chemical. The Company is yet to start its operation. ACI Formulations Limited through its voting rights (90% share holdings of ACI AgroChem Limited) controls the operating and financing activities of this entity..

**3 Consolidated Financial statements:**

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

**4 Selected explanatory notes:**

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2022. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

**5 Property, plant & equipment**

	<u>Figures in '000'</u>	
	<u>30- Sep -22</u>	<u>30-June -22</u>
	<u>Taka</u>	<u>Taka</u>
Opening balance	2,714,519	2,696,085
Addition during the period/year	24,905	31,042
Adjustment/disposal during thr period/year	-	(12,608)
	2,739,424	2,714,519
Accumulated depreciation at the end of period/year	(362,935)	(351,738)
<b>Closing balance</b>	<b>2,376,489</b>	<b>2,362,781</b>

	<u>30- Sep -22</u>	<u>30-June -22</u>
	<u>laka</u>	<u>laka</u>
<b>5(a) Consolidated property, plant &amp; equipment</b>		
Opening balance	2,718,220	2,701,045
Addition during the period/year	24,905	31,043
Adjustment/disposal during thr period/year	-	(13,868)
	<u>2,743,125</u>	<u>2,718,220</u>
Accumulated depreciation at the end of period/year	<u>(366,090)</u>	<u>(354,801)</u>
<b>Closing balance</b>	<u><u>2,377,035</u></u>	<u><u>2,363,419</u></u>
<b>6 Investments</b>		
Investment in subsidiaries	21,948	3,948
Investment in FDR	38,729	38,729
Investment in shares of ACI Motors Limited	75	75
	<u>60,752</u>	<u>42,752</u>
<b>6(a) Consolidated investments</b>		
Investment in FDR	38,729	38,729
Investment in Shares- ACI Motors Limited	75	75
	<u>38,804</u>	<u>38,804</u>
<b>7 Intangible assets</b>		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
<b>8 Inventories</b>		
Raw and packing materials	1,073,214	647,132
Finished goods	1,012,211	572,989
Goods in transit	196,768	138,930
Other inventories	25,383	25,196
Allowances for slow moving inventory	(37,973)	(23,659)
	<u>2,269,603</u>	<u>1,360,588</u>
<b>8(a) Consolidated inventories</b>		
Raw and packing materials	1,073,214	647,132
Finished goods	1,012,487	573,265
Goods in transit	196,768	138,930
Other inventories	25,383	25,196
Allowances for slow moving inventory	(38,249)	(23,935)
	<u>2,269,603</u>	<u>1,360,588</u>
<b>9 Trade receivables</b>		
Related parties	-	-
Other than related parties	1,539,491	1,334,999
	<u>1,539,491</u>	<u>1,334,999</u>
Allowances for doubtful debts	(225,231)	(222,898)
	<u>1,314,260</u>	<u>1,112,101</u>
Below six months	1,121,177	907,865
Over six months	418,315	427,133
Allowances for doubtful debts	(225,231)	(222,898)
	<u>1,314,260</u>	<u>1,112,101</u>
<b>9(a) Consolidated trade receivables</b>		
Related parties	-	-
Other than related parties	1,540,139	1,335,470
	<u>1,540,139</u>	<u>1,335,470</u>
Allowances for doubtful debts	(225,231)	(222,898)
	<u>1,314,908</u>	<u>1,112,572</u>
Below six months	1,121,353	908,336
Over six months	418,786	427,133
Allowances for doubtful debts	(225,231)	(222,897)
	<u>1,314,908</u>	<u>1,112,572</u>

	<u>30- Sep -22</u> <u>Taka</u>	<u>30-June -22</u> <u>Taka</u>
<b>10 Inter-company receivables</b>		
ACI Limited	473,708	785,674
ACI HelathCare Bangladesh Ltd.	35,717	33,179
ACI AgroChem Limited	941	-
Neem Laboratories (Pvt.) Ltd.	8,090	7,932
	<u>518,456</u>	<u>826,785</u>
<b>10(a) Consolidated inter-company receivables</b>		
ACI Limited	474,336	785,971
ACI HelathCare Bangladesh Ltd.	35,717	33,179
	<u>510,053</u>	<u>819,150</u>
<b>11 Advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staffs	76	99
Suppliers & others	26,823	31,774
VAT current account	18,930	(4,734)
	<u>45,829</u>	<u>27,139</u>
<b>Deposits:</b>		
Security deposits	10,147	10,026
Bank guarantee margin	4,784	4,784
	<u>14,931</u>	<u>14,810</u>
<b>Prepayments:</b>		
Prepaid expenses	1,778	2,864
	<u>1,778</u>	<u>2,864</u>
	<u>62,537</u>	<u>44,813</u>
<b>11(a) Consolidated advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staff	76	99
Suppliers & others	27,474	32,425
VAT current account	18,930	(4,734)
	<u>46,480</u>	<u>27,790</u>
<b>Deposits:</b>		
Security deposits	10,147	10,026
Bank guarantee margin	4,784	4,784
	<u>14,931</u>	<u>14,810</u>
<b>Prepayments:</b>		
Prepaid expenses	1,778	2,864
	<u>1,778</u>	<u>2,864</u>
	<u>63,188</u>	<u>45,464</u>
<b>12 Employee benefits</b>		
Defined benefit obligation	48,004	45,209
Other employee benefits	15,869	15,397
	<u>63,873</u>	<u>60,606</u>
<b>13 Other payables</b>		
Creditor for expenses	375,923	395,190
Advance from customer	-	4,478
Interest payable	43,483	10,284
Security money payable	25,912	25,868
Withholding tax and VAT payable	11,483	6,695
Workers' profit participation fund	22,381	17,282
	<u>479,182</u>	<u>459,797</u>

	<u>30- Sep -22</u>	<u>30-June -22</u>
	<u>Taka</u>	<u>Taka</u>
<b>13(a) Consolidated other payables</b>		
Creditor for expenses	376,456	395,717
Advance from customer	-	4,478
Interest payable	43,483	10,284
Security money payable	25,912	25,868
Withholding tax and VAT payable	11,483	6,695
Provision for workers' profit participation fund	22,381	17,282
	<u>479,715</u>	<u>460,324</u>
<b>14 Unclaimed dividend account</b>		
Unclaimed/ unpaid dividend	5,260	5,266
	<u>5,260</u>	<u>5,266</u>
	<u>for the period from</u>	
	<u>July 2022 to</u>	<u>July 2021 to</u>
	<u>September</u>	<u>September</u>
	<u>2022</u>	<u>2021</u>
	<u>Taka</u>	<u>Taka</u>
<b>15 Revenue</b>		
Crop Care & Public Health	1,065,191	815,853
Mosquito Coil	1,692	11,821
Aerosol	109,925	117,504
Paint	111,912	61,472
Others	4,171	13,176
	<u>1,292,891</u>	<u>1,019,826</u>
<b>15(a) Consolidated revenue</b>		
Crop Care & Public Health	1,065,191	815,853
Mosquito Coil	1,692	11,821
Aerosol	109,925	117,504
Paint	111,912	61,472
Others	4,708	13,465
	<u>1,293,428</u>	<u>1,020,115</u>

		for the period from	
		July 2022 to September 2022	July 2021 to September 2021
		Taka	Taka
<b>16</b>	<b>Cost of sales</b>		
	Opening stock	1,220,121	1,228,458
	Purchase	1,780,110	752,201
	Stock write off	(15,680)	935
		<u>2,984,551</u>	<u>1,981,594</u>
	Closing stock	(2,085,425)	(1,297,502)
		<u>899,126</u>	<u>684,092</u>
	Manufacturing expenses	54,660	50,009
		<u>953,786</u>	<u>734,101</u>
<b>16(a)</b>	<b>Consolidated cost of sales</b>		
	Opening stock	1,220,397	1,228,734
	Purchase	1,780,110	752,201
	Stock write off	(15,680)	935
		<u>2,984,827</u>	<u>1,981,870</u>
	Closing stock	(2,085,701)	(1,297,778)
		<u>899,126</u>	<u>684,092</u>
	Manufacturing expenses	54,660	50,009
		<u>953,786</u>	<u>734,101</u>
<b>17</b>	<b>Administrative, selling and distribution expenses</b>		
	Administrative expenses	47,707	38,160
	Distribution expenses	32,984	27,648
	Selling expenses	122,021	114,159
		<u>202,713</u>	<u>179,967</u>
<b>17(a)</b>	<b>Consolidated administrative, selling and distribution</b>		
	Administrative expenses	48,774	38,255
	Distribution expenses	32,984	27,648
	Selling expenses	122,021	114,159
		<u>203,780</u>	<u>180,062</u>
<b>18</b>	<b>Reconciliation of net operating cash flow</b>		
		for the period from	
		July 2022 to September 2022	July 2021 to September 2021
	<i>In Taka</i>		
	Profit after tax	74,023	52,749
	Adjustment for non cash items and others:		
	- Depreciation and amortization	11,197	10,424
	- Provisions	(12,977)	3,185
	- Net finance cost	33,199	20,886
	- Unrealized gain/(loss) on translation of foreign currency recei	(2,126)	-
	- Tax expense	(42,354)	(19,313)
	- Contribution to WPPF	5,099	3,806
	Changes in:		
	- Inventories	(893,329)	(115,120)
	- Trade and other receivables	(188,374)	(13,780)
	- Advances, deposit and prepayments	(17,724)	10,341
	- Trade and other payables, employment benefits'	153,142	(54,676)
	Cash generating from operating activities	<u>(880,223)</u>	<u>(101,498)</u>



18 (a)

**Reconciliation of consolidated net operating cash flow**

<i>In Taka</i>	<b>for the period from</b>	
	<b>July 2022 to September 2022</b>	<b>July 2021 to September 2021</b>
Profit after tax	73,280	52,775
Adjustment for:		
- Depreciation and amortization	11,289	10,517
- Bad debts and inventory loss/(recovery)	(12,977)	3,185
- Net finance cost	33,199	20,886
- Unrealized gain/(loss) on translation of foreign currency recei	(2,126)	-
- Tax expense	(42,300)	(19,284)
- Contribution to WPPF	5,099	3,806
Changes in:		
- Inventories	(893,329)	(115,120)
- Trade and other receivables	(188,550)	(13,837)
- Advances, deposit and prepayments	(17,724)	10,401
- Trade and other payables, employment benefits'	153,147	(54,647)
<b>Cash generating from operating activities</b>	<b>(880,991)</b>	<b>(101,318)</b>

<b>for the period upto</b>	
<b>July 2022 to September 2022</b>	<b>July 2021 to September 2021</b>

**19 Consolidated EPS, NAV per Share and NOCFPS:**

Weighted average number of ordinary shares (in thousand)	47,250	47,250
Consolidated profit attributable to equity holders of the Company (Taka '000)	73,373	52,774
Earnings per share (Taka)	1.55	1.12
Consolidated cash flows from operating activities (Taka '000)	(880,991)	(101,318)
Net operating cash flows per share (NOCFPS)	(18.65)	(2.14)
	<b><u>30- Sep -22</u></b>	<b><u>30-June -22</u></b>
	<b><u>Taka</u></b>	<b><u>Taka</u></b>
Consolidated net asset attributable to equity holders of the	3,186,060	3,112,687
Net asset value (NAV) per share	67.43	65.88

Consolidated revenue increased by around 27% over SPLY mainly due to higher sales in CC&PH and Paint business. Higher sales alongwith changes in product mix in CC&PH business, led to increase overall gross profit by 19% over SPLY whereas overall operating expenses increased by 13% . However, despite having increased financing cost caused by higher interest rate and utilization of working capital in line with increased sales, higher GP led to consolidated profit after tax of Tk. 73.28 Mn against Tk 52.78 Mn of SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS decreased due to inventory build-up for upcoming 2nd quarter .

## 20 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

**Crop Care and Public Health (CC & PH)** To manufacture and sell crop care and public health products.

**Mosquito Coil (M Coil)** To manufacture and sell mosquito coil products

**Aerosol** To manufacture and sell aerosol and air freshener products.

**Paint** To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on	
	30-Sep-22	30-Sep-21	30-Sep-22	30-Sep-21	30-Sep-22	30-Sep-21	30-Sep-22	30-Sep-21	30-Sep-22	30-Sep-21	30-Sep-22	30-Sep-21
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	1,065,191	815,853	1,692	11,821	109,925	109,418	111,912	61,472	3,566	13,176	1,292,286	1,011,740
Inter-segment revenues	-	-	-	-	-	8,086	-	-	1,142	289	1,142	8,375
Total revenue	1,065,191	815,853	1,692	11,821	109,925	117,504	111,912	61,472	4,708	13,465	1,293,428	1,020,115
Financing costs	(27,995)	(25,749)	(3)	-	(6,015)	-	(4,842)	(4,357)	(477)	(453)	(39,333)	(30,559)
Depreciation	(4,704)	(4,744)	(3,922)	(3,522)	(1,070)	(1,065)	(1,326)	(931)	(267)	(255)	(11,289)	(10,517)
Cost of sales excluding depreciation	(746,022)	(538,900)	(10,564)	(19,959)	(94,585)	(106,393)	(89,439)	(48,540)	(5,052)	(12,815)	(945,662)	(726,607)
Operating expenses excluding depreciation	(156,674)	(143,031)	(2,548)	(1,901)	(2,594)	(1,956)	(38,289)	(30,149)	(511)	(3)	(200,615)	(177,040)
Other income /(expense)	2,474	590	-	-	17	49	147	130	2,126	25	4,763	794
<b>Profit before tax</b>	<b>125,656</b>	<b>98,818</b>	<b>(14,578)</b>	<b>(12,883)</b>	<b>5,393</b>	<b>7,732</b>	<b>(20,745)</b>	<b>(21,256)</b>	<b>467</b>	<b>(30)</b>	<b>96,192</b>	<b>72,379</b>
<b>Reportable segment assets</b>	<b>3,566,513</b>	<b>2,541,485</b>	<b>553,719</b>	<b>579,231</b>	<b>843,387</b>	<b>684,141</b>	<b>517,113</b>	<b>518,135</b>	<b>1,856,362</b>	<b>2,146,384</b>	<b>7,337,095</b>	<b>6,469,376</b>
<b>Reportable segment liabilities</b>	<b>2,026,698</b>	<b>1,216,550</b>	<b>17,702</b>	<b>16,373</b>	<b>172,076</b>	<b>68,430</b>	<b>231,116</b>	<b>199,597</b>	<b>1,701,651</b>	<b>1,855,853</b>	<b>4,149,242</b>	<b>3,356,803</b>

\* Comparative figures of segment assets and segment liabilities are as of 30 June 2022.

21 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.